NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW)

CUSIP: N62509117

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class
Equity / *W EXP 99/99/999
Total 13F shares
2,281,964
Share change
+2,281,964
Total reported value
$1,913,061
Price per share
$0.87
Number of holders
20
Value change
+$1,913,061
Number of buys
20

Quarterly Holders Quick Answers

What is CUSIP N62509117?
CUSIP N62509117 identifies NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) as of Q4 2022

As of 31 Dec 2022, NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) was held by 20 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,281,964 shares. The largest 10 holders included HIGHBRIDGE CAPITAL MANAGEMENT LLC, Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., Ensign Peak Advisors, Inc, Exos TFP Holdings LLC, Bain Capital Life Sciences Investors, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Castle Creek Arbitrage, LLC, PEAK6 Investments LLC, and Westchester Capital Management, LLC. This page lists 20 institutional shareholders reporting positions in this security for the Q4 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.